Purpose: To evaluate the efficiency of transvaginal ultrasound in the early diagnosis of ovarian cancer. Methods: Screening transvaginal ultrasound has been annually performed during the last 2 years in asymptomatic women without familial history of ovarian cancer. When abnormalities were detected, the procedure was repeated after 4-6 weeks. If the findings disappeared, the study was repeated after 1 year. If the abnormality persisted, study was complemented with tumor markers, computed tomography and laparoscopic surgery. The findings were compared with a control group of women in whom ovarian transvaginal ultrasonography was formally indicated. Results: A total of 26007 transvaginal ultrasound were performed: 8813 (33.8%) belonged to the screening group and 17194 (66.2%) to the control group. In 14 patients of the screening group, a malignant tumor was diagnosed and histologically confirmed. The mean age of these patients was 45 years old (SD 12). Eleven of these tumors were stage I (seven Ia, and four Ic), two stage IIIc and one was a metastatic melanoma in both ovaries. Six lesions were borderline tumors (five serous and one mucinous). In the control group, 27 ovarian cancers were diagnosed in patients with a mean age of 48 years (SD 17). In this group, 11 tumors were in stage I, and six were borderline. Conclusions: Although consensus about the benefits of using transvaginal ultrasound as a screening procedure is not conclusive, our data reveals that tumors detected in patients screened with transvaginal ultrasound are in earlier stages when compared with those diagnosed in the control group. No differences were found in age and number of borderline tumors between both groups. Additional studies are needed to support this preliminary findings. P02Endometrial sampling during sonohysterography (SHGes) E. Ferrazzi, C. Lanzani, N. Ciminera & V. Conserva Purpose: To assess the diagnostic accuracy of sonohysterography (SHG) and endometrial sampling during SHG (SHGes) compared to traditional hysteroscopy and biopsy. Methods: Seventy-two consecutive patients with irregular bleeding and/or intracavitary abnormalities underwent transvaginal sonography (TVS) and SHG. SHG was performed with a 4.7-mm intrauterine catheter. In all patients, an endometrial biopsy was performed by a syringe vacuum aspiration at the end of SHG. Procedure-related pain was assessed. Sonographic findings at SHG were defined as normal, focal lesions or diffuse endometrial abnormality. In patients with diffuse endometrial abnormality, hysteroscopy and hysteroscopic guided biopsy were performed. In patients with focal lesions, an operative hysteroscopy was performed. Pathologic report was the gold standard. Results: Mean age was 48 years (interquartile range 38-54). At SHG, no pain, mild, and severe discomfort was reported by 75, 18 and 7% of patients, respectively. Fifty patients underwent hysteroscopic guided biopsy, 22 operative hysteroscopy. Hysteroscopic findings were compared to SHG-SHGes finding. (A) Benign lesions: in 56 cases SHG and SHG...

Fragestellung: Ziel der Untersuchung war, durch die Analyse der Schwangerschaftsverläufe HIV-infizierter Frauen und deren kindlichem Outcome an 10 deutschen gynäkologisch-geburtshilflichen HIV-Schwerpunktzentren die aufgetretenen Komplikationen und die resultierende Rate der vertikalen Transmission zu eruieren. Patientinnen und Methodik: Es wurden insgesamt 599 Schwangerschaften HIV-infizierter Mütter aus den Jahren 1999 -2003 aus 10 Einrichtungen der Schwerpunktversorgung in die Untersuchung aufgenommen. Folgende Parameter wurden hierbei erfasst: Infektionsmodus und -zeitpunkt der Mutter, Entbindungsmodus und Gestationsalter bei Geburt, CD4-Zellzahl bei Feststellung der Schwangerschaft sowie peripartal, Viruslast im Verlauf, ART (antiretrovirale Therapie) zuvor, ART in der Schwangerschaft, Schwangerschaftskomplikationen sowie kindlicher Infektionsstatus und allgemeiner kindlicher Gesundheitszustand. Ergebnisse: In 55 % der Fälle wurden eine oder mehrere Schwangerschaftskomplikationen dokumentiert, am häufigsten vorzeitige Wehentätigkeit (21,4%) und vorzeitiger Blasensprung (4,7 %). 595/599 Schwangerschaften endeten mit einer Lebendgeburt; davon wurden 98,3 % per Sectio caesarea entbunden. 20,3% der Schwangeren erlitten eine Frühgeburt. Fast 50 % der Frauen benötigten eine hochaktive antiretrovirale Mehrfachtherapie (HAART). Die kindliche Infektionsrate betrug 1,68 % (10 Kinder). Schlussfolgerung: Die Ergebnisse zeigen, dass eine in Abstract Objective: The study was performed to evaluate the course of pregnancies of HIV-infected women and their fetal outcome at 10 German reference gynecology/obstetrics departments to provide an overview of occurring complications and the rate of mother-to-child transmission (MTCT). Material and Methods: 599 pregnancies of HIV-infected mothers in the years 1999 -2003 at 10 German reference gynecology/obstetrics departments were recruited for evaluation. Data collected were: mode and time of infection and time of first diagnosis, mode and week of delivery, CD4 count and viral load at diagnosis of pregnancy and at delivery, antiretroviral therapy before and during pregnancy, pregnancy complications, fetal infection and general health status. Results: 595/599 pregnancies resulted in a live birth delivered in 98.3 % by cesarean section. In 55 % of the pregnancies one or more complications were documented. The most common were premature contractions (21.4 %) and premature rupture of the membranes (4.7 %). 20.3 % of the pregnant women delivered prematurely. Almost 50% of the women needed a highly active antiretroviral combination therapy (HAART). The vertical transmission rate was found to be 1.68 % (10 children). Conclusions:The study shows that the rate of mother-to-child transmission (MTCT) finally resulting after therapy according to the German-Austrian recommendations for HIV therapy in pregnancy is very low (under 2 %). Nevertheless, in order to achieve Originalarbeit 1058

No abstract

Objective To report and compare neoaortoiliac system reconstruction and cryopreserved human allograft in treating aortic graft infections. Methods We retrospectively analysed the data of the patients treated for aorto graft infections between January 2015 and May 2021 in our hospital. The clinical data, diagnostic procedures, and surgical options were evaluated. The primary endpoint of this study was the 30-day and 1-year mortality; secondary endpoints were major postoperative complications. Results We retrospectively reviewed a series of 31 consecutive patients (28 males; median age 72 years, range, 50–87 years) with aortic graft infection treated with NAIS (n = 20, 65%) or cryopreserved allograft (n = 11, 36%). The clinical presentation included fever attacks in 18 (58%) patients, abdominal pain in 15 (48%) patients, haemodynamic instability in 6 (19%) patients, and haematemesis in 2 (7%) patients. The median operative time of the NAIS was longer than CHA without a statistically significant difference (458 min vs. 359 min, p = .505). The postoperative morbidity for all patients was 81%, with no significant difference between NAIS and CHA groups (85% vs. 73%, p = .638). There was no limb thrombosis of the new reconstructions. Limb loss occurred in 4 (13%) patients, including 2 (10%) NAIS patients and 2 (18%) CHA patients. One NAIS patient developed complications in the form of a distal (femoral) disruption of the vein 15 days after surgery. There were no significant differences between NAIS and CHA groups in ICU stay (12 vs 8 days, .984) but in hospitalization (22 vs 33, p = .033). The most common bacteria isolated were staphylococci strains in 15 (48%). In 13 (36%) patients, candida was positive. The in-hospital 30-day and 1-year mortality for all patients was 16% (5/31) and 29% (9/31), with no significant differences between NAIS and CHA at 30 days (25% vs. 0, p = .133) or 1 year (35% vs. 18%, .429). Five NAIS patients died during the hospital stay; three of them had end-of-life decisions. After a median follow-up of 16 months (1–66 months), 12 (39%) patients died, including 9 patients with NAIS and 3 with CHA reconstructions. The causes of death included overwhelming sepsis in 5 (42%) patients, graft disruption in one (8%) NAIS patient, non–small cell lung cancer in one (8%) patient, COVID-19 in one (8%) patient and unknown causes (8%) in one. Conclusions Non-staged neoaortoiliac system reconstruction and cryopreserved human allografts show comparable short- and midterm results for treating aortic graft infections. However, both procedures remain challenging with high morbidity and mortality rates.

No abstract

Objective To evaluate and compare the outcomes of Candida- and non-Candida-associated aortic graft infections. Methods We retrospectively analyzed the data from patients treated for aortic graft infection from 2015 to 2021 in our hospital. Results A total of 66 patients (56 men; median age, 69 years; range, 50-87 years) were admitted with aortic graft infection, including 21 (32%) patients in the Candida group and 45 (68%) in the non-Candida group. The average time between initial operation and presentation of aortic graft infection was 50 months (range, 1-332 months). Graft-enteric fistulas (GEFs) were more often in the Candida group (57% vs 27%, P = .017). The most proven causative fungal specimen was C. albicans in 16 (76%) patients. Non-albicans Candida was found in 9% of all patients and 29% of the Candida patients. The median ICU length of stay was longer in the Candida group than non-Candida (10 vs 9 days, P = .012). Additionally, the median hospital length of stay was longer in the Candida group (33 vs 22 days, P = .048). There were no statistically significant differences between Candida and non-Candida groups according to the in-hospital mortality (24% vs 24%, P = .955), and 1-year mortality (38% vs 38%, P = .980). Conclusions Patients with bacterial and fungal aortic graft infections have high rates of morbidity and mortality. We found no significant differences in postoperative morbidity and mortality between Candida and non-Candida patients. However, the ICU and hospital length of stay were longer in the Candida group.

No abstract

No abstract